Study of Probuphine in Patients With Opioid Dependence

Inclusion Criteria: Patients must meet the following eligibility criteria: * Expected to complete 24 weeks of treatment in PRO-807 or PRO-808 * Voluntarily provide written informed consent prior to the conduct of any study-related procedures * Deemed appropriate for entry into this re-treatment study by the Investigator * Females of childbearing potential and fertile males must use a reliable means of contraception Exclusion Criteria: Patients are not eligible for enrollment if any of the following criteria are met: * Presence of aspartate aminotransferase (AST) levels ≥ 3 X upper limit of normal and/or alanine aminotransferase (ALT) levels ≥ 3 X upper limit of normal and/or total bilirubin ≥ 1.5 X upper limit of normal and/or creatinine ≥ 1.5 X upper limit of normal, measured at the time of the Week 20 Visit for the previous trial (PRO-807 or PRO-808), or any time less than 5 weeks prior to the Implant Visit. * Current diagnosis of chronic pain requiring opioids for treatment * Pregnant or lactating females * Current use of agents metabolized through cytochrome P450 3A4 (CYP 3A4) such as azole antifungals (e.g., ketoconazole), macrolide antibiotics (e.g., erythromycin), and protease inhibitors (e.g., ritonavir, indinavir, and saquinavir) * Current history of coagulopathy and anti-coagulant therapy (such as warfarin) * Current use of benzodiazepines other than physician prescribed use * Significant medical or psychiatric symptoms, cognitive impairment, or other factors w…